Cue Biopharma: Funding, Investors & Team (Sep 2026)
Cue Biopharma is a company that specializes in immunotherapy and is creating biologics that can selectively target disease-related T cells in order to treat cancer and autoimmune conditions. By mimicking the signals given by the body's antigen-presenting cells, Cue's biologics can prompt specific immune responses in the T cells associated with certain diseases. With a strong team of experts in protein biologics, immunology, and immuno-oncology, Cue has developed a range of promising drug candidates and is preparing to bring two leading programs to clinical trials. Based in Cambridge, Massachusetts, Cue is well-positioned to advance the field of immunotherapy.
Cue Biopharma has raised $102M across 5 funding rounds on record, the most recent an undisclosed round of $30.0M announced in Apr 2026.
That round is above the $8.0M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
Cue Biopharma Company Profile and Key Stats
Latest funding round on record: Apr 2026.
Cue Biopharma Funding Rounds
Cue Biopharma raised $30.0M in an undisclosed round announced in Nov 2022.
1.8 years later, an undisclosed round of $12.0M was announced in Sep 2024.
7 months later, an undisclosed round of $20.0M was announced in Apr 2025.
8 months later, an undisclosed round of $10.0M was announced in Dec 2025.
4 months later, an undisclosed round of $30.0M was announced in Apr 2026.
Cue Biopharma Founders and Leadership Team
No contact details are on record for this team yet.
Cue Biopharma Funding Compared to Other Biotechnology Startups
Cue Biopharma's latest round of $30.0M is above the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like Cue Biopharma in Biotechnology and Cambridge
Companies Similar to Cue Biopharma
Noveome Biotherapeutics, Inc. is an advanced biopharmaceutical company that focuses on groundbreaking…
XiltriX North America is an information technology company that specializes in monitoring, predictive…
Novir is an emerging diagnostic biotechnology company with an unmatched team of professionals and trusted…
Abcuro’s mission is to develop a new class of immune-modulatory bio-therapeutics for treating both…
Georgiamune Inc. is a privately-owned biotechnology company that specializes in advanced immunotherapy…
Bridge to Life was founded with the mission of improving organ transplants by licensing and developing new…
InduPro is a biotechnology firm that focuses on protein therapeutics and technologies related to cell-surface…
Paterna BioSciences, Inc. is a pioneering biotechnology company dedicated to solving the significant…
Legendary Bio's solidarity is a determined spotlight on introducing another period of quality guideline.
Cataract surgery is the single most common procedure performed in the United States annually. Despite…
InSitu Biologics is a developer of a drug delivery platform designed to focus on development of new and…
Remedium Bio is a gene therapy company in the Boston area that is dedicated to developing cures for severe…
Cue Biopharma Funding FAQs
What does Cue Biopharma do?
Cue Biopharma is a company that specializes in immunotherapy and is creating biologics that can selectively target disease-related T cells in order to treat cancer and autoimmune conditions. By mimicking the signals given by the body's antigen-presenting cells, Cue's biologics can prompt specific immune responses in the T cells associated with certain diseases. With a strong team of experts in protein biologics, immunology, and immuno-oncology, Cue has developed a range of promising drug candidates and is preparing to bring two leading programs to clinical trials. Based in Cambridge, Massachusetts, Cue is well-positioned to advance the field of immunotherapy.
How much funding has Cue Biopharma raised?
Cue Biopharma has raised $102M across 5 rounds on record. The most recent is an undisclosed round of $30.0M announced in Apr 2026.
When did Cue Biopharma last raise funding?
Cue Biopharma's most recent funding round on record is an undisclosed round of $30.0M, announced in Apr 2026.
Who founded Cue Biopharma?
FundedIQ lists Ronald Seidel (Founder), Usman "oz" (Founder) at Cue Biopharma.
Where is Cue Biopharma headquartered?
Cue Biopharma is based in Cambridge, Massachusetts, United States.
How many employees does Cue Biopharma have?
Cue Biopharma is in the 11-50 employee band.
How does Cue Biopharma's funding compare to other Biotechnology startups?
Cue Biopharma's latest round of $30.0M is above the $8.0M median round size for Biotechnology companies on FundedIQ across 4,179 tracked companies over the last two years.
About FundedIQ's Cue Biopharma Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Cue Biopharma is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Every newly funded startup with its round, its investors and its founders: delivered weekly by email, or searchable in the app.
Alerts from $19/mo · Pro from $99/mo. Card required, nothing charged until day 15, and we email you 3 days before that.